Cargando…

Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population

The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valen...

Descripción completa

Detalles Bibliográficos
Autores principales: Polistena, Barbara, Icardi, Giancarlo, Orsi, Andrea, Spandonaro, Federico, Di Virgilio, Roberto, d’Angela, Daniela
Formato: Online Artículo Texto
Lenguaje:English
Publicado: MDPI 2022
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784405/
https://www.ncbi.nlm.nih.gov/pubmed/36560441
http://dx.doi.org/10.3390/vaccines10122032
_version_ 1784857803715772416
author Polistena, Barbara
Icardi, Giancarlo
Orsi, Andrea
Spandonaro, Federico
Di Virgilio, Roberto
d’Angela, Daniela
author_facet Polistena, Barbara
Icardi, Giancarlo
Orsi, Andrea
Spandonaro, Federico
Di Virgilio, Roberto
d’Angela, Daniela
author_sort Polistena, Barbara
collection PubMed
description The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valent PCV were compared with the administration of 13-valent PCV and 15-valent PCV. Assuming a 100% vaccination of cohorts aged 65–74 years, in the (lifetime) comparison between 20-valent PCV and 13-valent PCV, the former is dominant (lower cost for a better health outcome). A reduction in disease events was estimated: −1208 deaths; −1171 cases of bacteraemia; −227 of meningitis; −9845 hospitalised all-cause nonbacteremic pneumonia cases (NBP) and −21,058 non-hospitalised. Overall, in the Italian population, a total gain of 6581.6 life years and of 4734.0 QALY was estimated. On the cost side, against an increase in vaccinations costs (EUR +40.568 million), other direct health costs are reduced by EUR 48.032 million, with a net saving of EUR +7.464 million. The comparison between 20-valent PCV and 15-valent PCV results in an Incremental Cost-Effectiveness Ratio (ICER) of EUR 66 per life year gained and EUR 91 per QALY gained. The sensitivity analyses confirm the robustness of the results. We can conclude that the switch to 20-valent PCV is a sustainable and efficient investment.
format Online
Article
Text
id pubmed-9784405
institution National Center for Biotechnology Information
language English
publishDate 2022
publisher MDPI
record_format MEDLINE/PubMed
spelling pubmed-97844052022-12-24 Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population Polistena, Barbara Icardi, Giancarlo Orsi, Andrea Spandonaro, Federico Di Virgilio, Roberto d’Angela, Daniela Vaccines (Basel) Article The availability of a new 20-valent pneumococcal conjugate vaccine (PCV) makes it appropriate to assess its cost-effectiveness. This was evaluated by adopting the Italian National Health Service perspective, using a cost consequences Markovian model. The expected effects of vaccination with 20-valent PCV were compared with the administration of 13-valent PCV and 15-valent PCV. Assuming a 100% vaccination of cohorts aged 65–74 years, in the (lifetime) comparison between 20-valent PCV and 13-valent PCV, the former is dominant (lower cost for a better health outcome). A reduction in disease events was estimated: −1208 deaths; −1171 cases of bacteraemia; −227 of meningitis; −9845 hospitalised all-cause nonbacteremic pneumonia cases (NBP) and −21,058 non-hospitalised. Overall, in the Italian population, a total gain of 6581.6 life years and of 4734.0 QALY was estimated. On the cost side, against an increase in vaccinations costs (EUR +40.568 million), other direct health costs are reduced by EUR 48.032 million, with a net saving of EUR +7.464 million. The comparison between 20-valent PCV and 15-valent PCV results in an Incremental Cost-Effectiveness Ratio (ICER) of EUR 66 per life year gained and EUR 91 per QALY gained. The sensitivity analyses confirm the robustness of the results. We can conclude that the switch to 20-valent PCV is a sustainable and efficient investment. MDPI 2022-11-28 /pmc/articles/PMC9784405/ /pubmed/36560441 http://dx.doi.org/10.3390/vaccines10122032 Text en © 2022 by the authors. https://creativecommons.org/licenses/by/4.0/Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
spellingShingle Article
Polistena, Barbara
Icardi, Giancarlo
Orsi, Andrea
Spandonaro, Federico
Di Virgilio, Roberto
d’Angela, Daniela
Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
title Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
title_full Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
title_fullStr Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
title_full_unstemmed Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
title_short Cost-Effectiveness of Vaccination with the 20-Valent Pneumococcal Conjugate Vaccine in the Italian Adult Population
title_sort cost-effectiveness of vaccination with the 20-valent pneumococcal conjugate vaccine in the italian adult population
topic Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9784405/
https://www.ncbi.nlm.nih.gov/pubmed/36560441
http://dx.doi.org/10.3390/vaccines10122032
work_keys_str_mv AT polistenabarbara costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation
AT icardigiancarlo costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation
AT orsiandrea costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation
AT spandonarofederico costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation
AT divirgilioroberto costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation
AT dangeladaniela costeffectivenessofvaccinationwiththe20valentpneumococcalconjugatevaccineintheitalianadultpopulation